Cargando…
New Hypoglycemic Drugs: Combination Drugs and Targets Discovery
New hypoglycemic drugs, including glucagon-like peptide 1 receptor agonists (GLP-1RA), dipeptidyl peptidase-4 inhibitors (DPP-4i) and sodium-glucose cotransporter 2 inhibitors (SGLT-2i), which brings more options for the treatment of type 2 diabetes (T2DM). They are generally well tolerated, althoug...
Autores principales: | Ni, Xiayun, Zhang, Lei, Feng, Xiaojun, Tang, Liqin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9295075/ https://www.ncbi.nlm.nih.gov/pubmed/35865956 http://dx.doi.org/10.3389/fphar.2022.877797 |
Ejemplares similares
-
Repositioning of Hypoglycemic Drug Linagliptin for Cancer Treatment
por: Li, Yong, et al.
Publicado: (2020) -
Editorial: New Paradigms in Neuroscience and Related Targets for Drug Discovery
por: Salomone, Salvatore
Publicado: (2020) -
Evaluation of mulberry leaves’ hypoglycemic properties and hypoglycemic mechanisms
por: Chen, Sikai, et al.
Publicado: (2023) -
Microglial Drug Targets in AD: Opportunities and Challenges in Drug Discovery and Development
por: Biber, Knut, et al.
Publicado: (2019) -
Synthetic Biology Speeds Up Drug Target Discovery
por: Xie, Yixuan, et al.
Publicado: (2020)